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Abstract: Cardiac diagnostic or therapeutic testing is an essential tool for diagnosis and 
treatment of cardiovascular disease, but it also involves considerable exposure to ionizing 
radiation. Every exposure produces a corresponding increase in cancer risk, and risks are 
highest  for  radiation  exposure  during  infancy  and  adolescence.  Recent  studies  on 
chromosomal biomarkers corroborate the current radioprotection assumption showing that 
even  modest  radiation  load  due  to  cardiac  catheter-based  fluoroscopic  procedures  can 
damage the DNA of the cell. In this article, we review the biological and clinical risks of 
cardiac imaging employing ionizing radiation. We also discuss the perspectives offered by 
the use of molecular biomarkers in order to better assess the long-term development of 
health effects. 
Keywords:  ionizing  radiation;  DNA  damage;  cancer  risk;  biomarkers;  genetic 
polymorphisms 
 
 
1. Introduction 
 
The increasing exposure to medical radiation in Western countries is a hot issue that the medical 
community needs to appreciate because it may likely result in an increase in the incidence of imaging-
related cancer in the future [1-3]. 
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Medical  use  of  radiation  is  the  largest  man-made  source  of  radiation  exposure  to  the  general 
population [1]. According to the recent report on medical radiation exposures to the population in the 
United States, the pro-capite collective dose of radiation received from clinical imaging has increased 
by > 700% between 1980 and 2006 [2]. 
The  current  annual  collective  dose  radiation  exposure  received  by  the  US  population  has  been 
calculated  as  roughly  equivalent  to  the  total  worldwide  collective  dose  generated  by  the  nuclear 
catastrophe at Chernobyl [2,3]. 
Many  cardiac diagnostic or therapeutic testing,  such as cardiac catheterization, CT and nuclear 
medicine scans, accounting for > 50% of all imaging examinations, involve considerable exposure to 
ionizing  radiation  [4-6].  A  contemporary  cardiac  patient  is  exposed  to  a  significant  cumulative 
effective dose (a median cumulative effective dose of 60 mSv per head) from multiple tests, often 
repeated needlessly [6,7]. 
Three central principles provide the foundation for radiation protection: 1) justification (the benefit 
of radiation exposure outweighs any accompanying risk; 2) optimization (total exposure remains as 
low as reasonably achievable, ALARA principle), and 3) dose limits (dose limits are applied in order 
to ensure that no one is exposed to an unacceptably high risk).  
In cardiological practice, therefore, every effort should be done to justify the indications and to 
optimize the doses during ionising testing. The imaging examination should confer a relevant clinical 
information on patient management, i.e. the benefit deriving from the examination must be greater 
than the long-term risk associated with the exposure [6,8]. 
The evaluation of the health effects of low-dose ionizing radiation has always been the main issue 
in radiological protection.  In this article, we review the biological and clinical risks of diagnostic 
imaging employing ionizing radiation as well as to discuss the perspectives offered by the use of 
surrogate molecular biomarkers in order to better assess the long-term development of health effects. 
 
2. Biological Effects of Ionizing Radiation 
 
The  biological  effects  of  ionizing  radiation  are  divided  into  two  categories:  deterministic  and 
stochastic effects [9-13]. Deterministic effects, such as erythema or cataracts, have a threshold dose 
below  which  the  biological  response  is  not  observed  (Table  1).  Some  cardiological  interventional 
procedures  with  long  screening  times  and  multiple  image  acquisition  (e.g.  percutaneous  coronary 
intervention, radio-frequency ablation, etc.) may give rise to deterministic effects in both staff and 
patients [14,15]. 
A stochastic effect is a probabilistic event and there is no known threshold dose (Table 1). The 
likelihood of inducing the effect, but not the severity, increases in relation to dose and may differ 
among individuals. In fact, the effect of low doses of radiation – less than 50 mSv – do not cause an 
immediate problem to any body organ, but spread out over long periods of time after exposure.  
Damage to DNA, which carries the genetic information in chromosomes in the cell nucleus, is 
considered to be the main initiating event by which radiation damage to cells results in development of 
cancer and hereditary disease in the future children of exposed parents [9-13]. 
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Table 1. Biological effects of ionizing radiation. 
  Deterministic effects  Stochastic effects 
Dose   Medium-High  Low 
Occurrence time  Short  Long 
Threshold dose   Yes  No 
Cell Biology  Cell Death  DNA damage 
Clinical effects  Skin lesions, erythema, ulcers, 
epilation, cataracts, permanent sterility 
Cancer, genetic effects 
 
Ionizing radiation exposure produces long-term health risk through, both directly or indirectly (free 
radical interaction), damage to  cellular DNA, producing oxidized bases, bulky  DNA adducts, and 
DNA strand breaks.  
The  cell  has  repair  mechanisms  against  damage  induced  by  radiation  as  well  as  by  chemical 
carcinogens. Consequently, biological effects of low dose radiation on living cells may result in three 
outcomes: (1) injured or damaged cells repair themselves, resulting in no residual damage; (2) cells 
die; or (3) cells incorrectly repair themselves resulting in a biological change. 
Therefore,  the  biological  effects  of  a  stochastic  effect  are  at  DNA  level  and  they  may  not  be 
detected.  The  basic  concept  is  that  physical  steps  that  lead  to  energy  deposition  and  free  radical 
formation occur within 10
-5 to 10
-6 seconds, whereas the biological expression of physical damage may 
occur a second or decades later [10] (Figure 1). 
 
Figure 1. Chemical and biological effects by ionizing radiation. On the left side: from 
physical interaction (a few milliseconds) to clinical effects (decades later). On the right 
side: the corresponding molecular (DNA damage), cellular (cell damage or proliferation), 
and clinical events (such as cancer). Redrawn and modified from ref. [10]. 
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Radiation–induced mutation contribute to the multi-step process of human cancer arising from the 
accumulation of multiple genetic abnormalities (over-expression of genes, deletion of genes, or gene 
mutations), some of which must occur in critical genes that regulate proliferation and differentiation. 
Genetic effects are the result of a mutation produced in the reproductive cells of an exposed individual 
that are passed on to their offspring. These effects may show up as birth defects or other conditions in 
the future children of the exposed individual and succeeding generation.  
Adverse  hereditary  effects  that  could  be  attributed  to  radiation  have  not  been  found,  in 
epidemiological studies of children whose parents were exposed to radiation [12,13]. However, studies 
conducted on mice and other organisms have produced extensive data showing that radiation-induced 
cell mutations in sperm and eggs can be passed on the offspring [12]. Thus, there is no reason to 
believe that humans would be immune to this sort of harm [12]. 
 
3. Clinical Risk of Medical Ionizing Radiation Exposure 
 
Carcinogenesis, teratogenesis and heritable effects are the main health risks with ionizing radiation. 
Other non-cancer adverse effects -especially atherosclerotic cardiovascular and cerebrovascular risk-
can occur following high-dose radiation therapy, but more research is needed to fully assess these 
outcomes at low and moderate doses [12,13]. 
Radiation  risks  are  reviewed  at  regular  intervals  by  international  and  national  radiological 
organizations by considering scientific progress worldwide in order to reach a balanced view of the 
risks involved. 
The current consensus of these regulatory bodies is that for radiation protection purposes the most 
appropriate  risk  model  at  low  doses  is  the  so-called  linear  no-threshold  (LNT)  model,  without 
threshold safe dose.  
During last years, however, two opposing concept to LNT model have emerged. In fact, some have 
argued that risks are smaller than predicted by the linear no-threshold model [16], or that low doses of 
radiation  may  even  be  beneficial  because  organisms  possess  the  ability  to  respond  to  low-dose 
radiation  by  stimulating  certain  protective  functions  (radiation  adaptive  response),  including 
antioxidative capacity, DNA repair functions, apoptosis [17]. 
Some  postulate  that  low  doses  of  radiation  are  more  harmful  than  previously  thought  because 
damage occurs not to the cell that was exposed to radiation but also to surrounding cells (bystander 
effects) [18]. 
The most recent update of the health risks of exposure to low levels of ionizing radiation comes 
from the National Research Council Committee on the Biological Effects of Ionizing Radiation Report 
(BEIR VII) of the National Academy of Sciences [12]. 
The evidence considered by BEIR VII comprises epidemiological studies of human populations, 
including  atomic  bomb  survivors,  patients  exposed  to  radiation  from  diagnostic  and  therapeutic 
medical studies, as well as studies from occupational exposures and from exposure due to releases of 
radioactive materials into the environment [12,19]. 
Direct epidemiological evidence (A-bomb survivors and other groups) demonstrated that there is a 
linear relationship between risk of cancer and dose between about 50 mSv and 2.5 Sv, but the risk of Int. J. Environ. Res. Public Health 2009, 6                 
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cancer associated with lower dose remains uncertain, because the natural incidence of cancer in any 
population is high. 
BEIR  VII  still  reconfirmed  that  the  LNT  model  is  the  best  model  to  estimate  radiation  risks, 
continuing to support the well-established radiobiological concept that no radiation doses -no matter 
how small- can be considered completely safe. 
BEIR VII indicated that a single adult population effective dose of 10 mSv results in a 1 in 1,000 
lifetime risk of developing radiation-induced solid cancer or leukaemia [12]. However, approximately 
42 people out of 100 are expected to develop cancer for other reasons [12]. 
It is worth noting that many cardiac ionizing procedures have effective dose estimates in the range 
of 10 to 25 mSv [7]; thus, it is not be uncommon for a patient to exceed the dose of 50 mSv, even in a 
single hospital admission for a single problem, most commonly a suspicion of coronary artery disease. 
 
Figure 2. Graphical representation the cumulative exposure of doses in multiples of dose 
from a simple chest x ray (y axis, left) and corresponding cancer risk (y axis, right) cancer 
risk  and  radiation  dose  (in  multiples  of  dose  from  a  simple  chest  x  ray)  for  a  typical 
cardiological patients undergoing to five radiological examinations. Redrawn and modified 
from ref. [4]. 
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For  instance,  a  50-year-old  man  who  undergoes  one  thallium  scan  stress  tests,  one  64-slice 
computed  tomography  coronary  angiography,  one  coronary  angiography,  and  one  coronary 
intervention  would  receive  an  effective  radiation  dose  of  about  71  mSv  and  thus  would  have  an 
additional subsequent lifetime risk for developing cancer of about 1 in 150 patients (Figure 2). 
Furthermore,  it  is  very  important  to  underline  those  children  and  young  adults  are  especially 
vulnerable since they have more rapidly dividing cells and a greater life expectancy [12]. For example, 
the overall risk of developing cancer (incidence and mortality) from the same dose of radiation for a 1-
year old infant is 10-15 times greater than a 50 year old adult, and female infants have almost double 
the risk than that of male infants. Figure 3 shows the estimated risk of cancer mortality as a function of 
age at exposure for both males and female. 
 
Figure 3. Radiation- Induced Risk of Cancer on Age and Gender by using the BEIR
 VII estimates. 
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Therefore, alternative diagnostic modalities that do not involve the use of ionizing radiation should 
be considered in the evaluation of young individuals in order to minimize cancer risk [20,21]. 
 
4. The Limitation of Risk Assessment from Epidemiological Studies 
 
Epidemiological studies are meritorious and important in order to estimate the health risk from 
radiation exposure. However, quantifying the risk at low dose below 50 mSv in humans may not be 
accurately estimated by any epidemiological studies because of a very high background incidence rate 
of cancer and numerous confounding factors. Most epidemiological studies have inherent limits of 
being statistically underpowered because studies with very large sample size are required in order to 
quantify the risks of very low doses of radiation. For instance, it has been estimated that more than 5 
million people are required in order to directly quantify the risk of cancer from exposure to doses of 
radiation of 10 mSv or less [22]. 
At low doses, the risk is essentially estimated by extrapolation of the dose-effect curve obtained 
from high doses. Because of limitations in the data used to develop risk models, risk estimates are 
uncertain, and estimates that are a factor of two or three larger or smaller cannot be excluded [12]. Int. J. Environ. Res. Public Health 2009, 6                 
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Therefore, additional research is needed to better understand the biological events that lead to the 
development of most cancers, as recently indicated in the Recommended Research Needs by the BEIR 
VII report [12]. 
In particular, the BEIR VII committee has recommended medical studies of patients, especially 
infants  who  have  had  a  significant  medical  radiation,  such  as  exposure  related  to  cardiac 
catheterization [12]. 
More research is also recommended needed on DNA damage chromosomal aberrations, and gene 
mutations caused by radiation exposure, as well as the role of genetic susceptibility in modulating low 
dose radiation response [3,12]. 
In order to overcome the severe practical limitations of the epidemiological approach, an alternative 
strategy  is  based  on  the  use  of  biomarkers  as  early  predictors  of  delayed  health  outcomes  and 
susceptible populations [23]. 
 
5. Biomarkers in the Assessment of Radiation Exposure Support BEIR VII Estimates 
 
The  incorporation  of  molecular  and  cellular  biomarkers  (molecular  epidemiology)  into 
epidemiological  studies  has  grown  exponentially  during  recent  years  in  order  to  better  examine 
relationships  between  environmental  hazards  and  human  health  effects.  The  use  of  biomarkers  is 
expected  to  identify  important  mechanistic  insight  into  the  pathogenesis  of  disease  processes  and 
reduce the time gap exposure and recognition of disease-relevant effects. 
 
Figure 4. Biomarkers are the key elements of molecular epidemiology and may open the 
“black box” from exposure to disease. 
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One of the goals of molecular epidemiology studies is to use biomarkers in order to develop new 
and more effective strategies to reduce risk, such as exposure monitoring, health surveillance and 
individual risk characterization [24,25]. Different biomarkers reflecting exposure to and early effects 
of carcinogens, as well as individual genetic susceptibility to them, have become available and are 
being applied in population-based (molecular epidemiology) (Figure 4). 
Biomarkers of early effect with relevance to the carcinogenic process include the evaluation of 
chromosomal DNA damage in peripheral blood lymphocytes in the form of chromosome aberrations 
and micronuclei [23]. During recent years, indeed, large studies have provided consistent evidence that 
high levels of chromosomal DNA damage in peripheral blood lymphocytes are early predictors of 
cancer risk [26,27]. The use of chromosomal biomarkers may assist in the difficult task of assessing 
the risk of radiation-induced oncogenic effects. As such, they can complement classic epidemiological 
studies  that  use  disease  endpoints  and  require  millions  of  people  followed-up  for  several  decades 
(Figure 5). 
 
Figure 5. Chromosomal aberrations in peripheral blood lymphocytes: biomarkers of early 
effect and cancer risk assessment. Redrawn and modified from ref. [26]. 
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Indeed, we have recently used chromosomal biomarkers as intermediate endpoint in carcinogenesis 
in order to assess the potential risk due to cardiac catheter-based fluoroscopic procedures, magically in 
the line of Research Needs as outlined by the BEIR VII report on 2006 [12] and by the White Paper of 
the American College of Radiology on effects of medical radiation released on 2007 [3]. Our results 
corroborated the current radioprotection assumption that even modest radiation load can damage the 
DNA of the cell. Int. J. Environ. Res. Public Health 2009, 6                 
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Invasive cardiovascular procedures can damage the DNA of the cell to be detectable-acutely and in 
the long-term as increased chromosomal DNA damage in circulating lymphocytes that represent an 
intermediate endpoint of cancer [28,29]. 
Importantly, we observed that the lifetime exposure of a young adolescent with congenital heart 
disease  in  the  range  of  20  mSv  is  associated  with  a  dramatically  200%  increased  frequency  of 
chromosomal DNA damage when compared to age- and sex-matched control subjects [28]. 
Furthermore, we also showed that contemporary interventional cardiologists have an increased rate of 
chromosomal  somatic  DNA  damage,  reflected  in  higher  frequency  of  micronuclei  versus  clinical 
cardiologists [30]. 
Actually, interventional cardiologists have a per-capita per year exposure two-to three times higher 
than that of radiologists [31]. Cumulative doses after 30 years of working life can be as high as 100 to 
250  mSv,  corresponding  to  a  whole  body  dose  equivalent  to  5,000  to  12,500  chest  X-rays.  This 
exposure gives an estimated lifetime attributable risk of cancer incidence in the range of 1 cancer in 
100-1 in 200 exposed subjects [32]. 
However,  the  amount  of  this  damage  varies  and  is  only  weakly  related  to  the  duration  of 
professional exposure, suggesting that an individual predisposition may play an important role in the 
cellular response to radiation exposure. 
Indeed, it is believed that genetic factors may play a crucial role in cellular responses to radiation 
and those common single-nucleotide polymorphisms (SNPs) in DNA repair genes can lead to heritable 
predisposition to cancer. Accordingly, considerable effort is being expended in the search for SNPs 
involved in different DNA repair pathways, including base excision repair (BER) pathway and double 
strand break repair process (DSB), which might act as cancer susceptibility genes [33-35]. 
Interestingly, we recently found that harbouring two or more risk alleles of DNA repair genes, 
contribute to chromosomal DNA damage levels in interventional cardiologists, suggesting that the risk 
estimates at the population level can be highly inaccurate at the individual level [36]. 
A  significant  association  between  breast  cancer  risk  and  genetic  polymorphisms  has  been  also 
reported among women exposed to low levels of ionizing
 radiation from medical procedures [37,38]. 
Subgroups  of  women  who  are  carriers  of  mutation  in  DNA  repair  genes  including  BRCA-1  and 
BRCA-2, showed a significantly increased breast cancer risk associated with exposure to diagnosticX-
rays, especially to the chest [37,38]. 
Therefore,  the  application  of  biomarkers  in  molecular-epidemiological  researches  constitutes  a 
promising new strategy for enhancing exposure assessment as well as for a better understanding of
 the 
mechanisms of action and dose-response relationships for
 ionizing radiation and human cancer. 
In general, there is a need to continue epidemiological as well as to integrate these investigations 
with  laboratory  studies  in  order  to  provide  new  insights  in  low  dose  radiation  risks,  particularly 
encountered in modern medicine. 
Future molecular epidemiologic studies incorporating genetic polymorphisms and biomarkers of early 
effects  provide  the  rationale  for  identifying  at-risk  susceptible  or  resistant  subpopulations  in  order  to 
develop better radiation protection programmes.  
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